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PREFACE 
Cholangiocarcinoma (CCA) is the most lethal type of primary liver tumors (PLCs), responsible for 20% 
of liver-related deaths. Persistent increases in incidence and mortality rates have been observed 
over the past decades. The median survival of CCA is only 6 to 8 months, and the 5-year survival rate 
has remained at 10% since the 1980’s. Importantly, the incidence of CCA is estimated to continue to 
increase the next 10 years, which could be speculated as a cause of an aberrant rearrangement of 
the hepatic metabolism owing changes in our lifestyles. The rise in mortality reflects the limited 
treatment options. Failure of current chemotherapy to extend median survival beyond 1 year 
highlights the extensive innate and rapidly acquired chemoresistance of these tumors, though the 
underlying molecular perturbations remain opaque. 
Genomic heterogeneity is a hallmark of CCA. As a consequence, drug resistance is a major concern in 
the clinical management of these patients with more than 50% risk of recurrence after surgery. At 
the time of diagnosis 70% to 90% of patients present locally advanced and metastatic disease thus; 
curative surgical resection is not an option. Notably, a significant proportion of the mutational 
landscape in CCA comprises recurrent mutations in epigenetic regulators, implying extensive epi- 
and genome-wide consequences arising from mutant isoform activities. In this chapter, we will focus 
on understanding the mechanisms that contribute to the risk of CCA and leverage molecular data to 
elucidate markers, predictive factors of risk that may impact our current clinical management of 
cholangiocarcinoma. Importantly, we will emphasize advanced CCA and discuss if the molecular 
make of these tumors are different from resected cholangiocarcinoma. The current efforts in 
utilizing genome-based characterization and patient stratification to direct clinical decisions 
predominantly implicate patients with resectable disease. 
 
Genetic alteration and putative risk factors in cholangiocarcinoma 
Data on the inherited risk factors modulating genetic susceptibility to CCA is scarce. This might be 
due to the rarity and complexity of the disease, which renders collection of large, well-powered 
cohorts of patients troublesome. Nevertheless, a whole-genome sequencing (WGS) study of the 
Icelandic population recently identified a potential CCA-risk gene1. In brief, this consortium 
sequenced the genomes of 2,636 Icelanders identifying 1.5 million insertions and deletions (InDels) 
and 20 million single nucleotide polymorphisms (SNPs)1. The analysis demonstrated that several 
mutations in the ABCB4 gene, which encodes for the hepatobiliary phosphatidylcholine translocase, 
increase the odds ratio of developing liver disease. Interestingly, the study showed the association 
between ABCB4 mutations and an increased risk of bile duct cancers1. Of note, so far patients with 
rare ABCB4 mutations are known to develop progressive familial intrahepatic cholestasis type 3 
(PFIC3) in childhood or a milder phenotype (low phospholipid associated-cholelithiasis (LPAC) 
syndrome2,3) in adulthood. LPAC syndrome is defined by early-onset cholelithiasis (< 40 years of age), 
concurrent gallbladder, bile duct and/or intrahepatic cholesterol gallstones, and recurrence of biliary 
symptoms after cholecystectomy3,4. The Icelandic GWAS found that the common ABCB4 variants 
might be determinants of cholestasis of pregnancy, liver cirrhosis, and hepatobiliary cancer5. These 
observations are in concordance with another GWAS of 1,042 Indian patients with gallbladder 
cancer (GBC), including 1,709 controls, which identified significant associations between SNPs in 
ABCB4 and the risk of GBC. Although, the Abcb4-knockout mouse, which is deficient for the 
orthologous murine gene develops hepatocellular cancer (HCC), and not CCA, the above GWAS 
findings highlight the effects of genetic variants in hepatobiliary transporters on the development of 
CCA. Indeed, ABCB4 regulates the biliary concentration of phosphatidylcholine, whereas the levels of 
other bile compounds (namely sterols and bile salts) are determined by the secretion (efflux) rates of 
the corresponding ATP-dependent canalicular (basolateral) transporters of hepatocytes6-8. For 
example, the ATP-binding cassette, subfamily B member 11 (ABCB11) represents the bile salt export 
pump (BSEP). Mutations in ABCB11 gene cause progressive familial intrahepatic cholestasis type 2 
(PFIC2) with decreased bile acid secretion, accumulation of bile salts in the liver parenchyma, and 
liver injury. PFIC2 manifests typically within the first six months of life with pruritus and jaundice as 
well as progressive fibrosis, which in most cases results in liver cirrhosis within the first two years of 
life. Interestingly, in adulthood, the risk for developing hepatobiliary cancers is also increased. 
Indeed, 15% of patients with BSEP-deficiency might develop HCC or CCA9,10. However, a clear 
pathogenesis of this association has not been fully elucidated. 
Not only genetic variants in the hepatobiliary transporters have been implicated in the increased risk 
of developing CCA. The pathogenesis of CCA remains unclear but it has for long been appreciated 
that patients with primary sclerosing cholangitis (PSC) are at increased risk of developing CCA. PSC is 
a rare (prevalence 1:10.000) inflammatory disease of the bile ducts. Hence, it is plausible that 
genetic variants that are associated with an increased risk of developing PSC might modulate the risk 
of CCA itself. Also, this risk may be in the absence of chronic inflammation of bile ducts. As such, 
Krawczyk et al.11 analysed a specific SNP (rs3197999) in the MST1 gene in a cohort of European 
patients with CCA. This variant was previously associated with an increased risk of PSC in a GWAS 
study12. The variant allele (rs3197999) is a missense mutation that results in p.R689C amino acid 
substitution within the β-chain of MSP (MSPβ). The MSP/RON signalling axis is involved in several 
aspects of cancer-relevant and cellular processes, such as chemotaxis, innate immunity and 
macrophage activation. Given this data, the rs3197999 variant was analysed in a cohort of 223 CCA 
patients (including three with PSC-CCA) and in 355 cancer- and PSC-free controls11. Interestingly, the 
cancer group departed from Hardy-Weinberg equilibrium (p=0.022) and exhibited a trend for 
rs3197999 [A] overrepresentation (31% vs. 26%: p=0.10). Homozygous rs3197999 [AA] carriers 
showed significantly increased overall (OR=1.97; p=0.023) and PSC-unrelated biliary tract cancer risk 
(OR=1.84; p=0.044), as compared to the homozygous carriers of the common MST-1 allele. The 
association was the most pronounced in patients with extrahepatic tumors and proved to be 
significant in multivariate models (p<0.05), validating the [AA] genotype as an independent CCA risk 
factor, indicating a possible modulation of inflammatory responses and/or altered MSP/RON 
signalling11. Chaiteerakij et al.13 have investigated the consequences of other selected inflammation-
modulating SNPs on the risk of developing CCA and patient’s survival. In this case-control analysis13, 
a total of 370 patients with CCA and 740 matched healthy controls were included. The authors 
selected eighteen variants in nine genes. Although two of the selected variants (rs2143417 and 
rs689466) in cyclooxygenase 2 (COX2) were associated with the risk of CCA in the discovery cohort 
(P=0.0003 and P=0.005, respectively), these associations failed to reach significance in the validation 
cohort (P>0.05), making the results difficult to interpret. In turn, Fingas et al.14 analysed, the 
association between the G protein subunit-β 3 (GNB3) 825C>T, B-cell-lymphoma-2 (Bcl2) 938C>A, 
and myeloid cell leukemia-1 (Mcl1) 386C>G, genetic variants and their associated clinical outcomes 
in the setting of CCA. This analysis14 was based on a cohort of 40 adult Caucasian patients with 
extrahepatic CCA (eCCA) and 40 age- and sex-matched healthy controls. Their analysis showed that 
carriers of GNB3 825C>T SNP have a longer overall survival as compared to the carriers with the T 
allele14. Other variants, enhancer of zeste homolog 2 (EZH2) (rs2417954615), nuclear factor 
(erythroid derived 2)-like 2 (NRF2)16 or alpha1-antitrypsin (α1AT) deficiency Z heterozygosity17, have 
been linked to increased risk of CCA. However, most of these studies were performed in single 
cohorts and are still awaiting validation in large groups of patients with CCA. Indeed, based on the 
relative rarity of CCA most of the collected cohorts lack the power to significantly detect the risk 
variant and later to replicate the genetic findings. Secondly, larger cohorts with available germline 
DNA are also required to analyze the genetic background in different CCA subtypes. Overcoming 
these limitations is one of the aims of the European Network for the Study of Cholangiocarcinoma 
(ENS-CCA), which is participating in the international CCA GWAS study currently underway. 
Although, we currently lack common genetic variants that substantially show an increased risk of 
developing CCA, genetic analyses might already be incorporated in the clinical management of 
patients with PSC, who are at-risk of developing CCA. Of note, it is recommended that patients with 
PSC should undergo regular surveillance and assessment of the serum marker Carbohydrate antigen 
19-9 (CA19-9) to facilitate the early detection of the CCA. Interestingly, it has been shown that 
genetic variants of fucosyltransferases 2 and 3 (FUT2/3) might modulate the serum levels of CA19-9. 
Based on this information, Wannhof et al.18 incorporated the FUT2/3 variants in the analysis of 433 
individuals with PSC, including 41 patients who had progressed to PSC-CCA18. Based on the genetic 
variants of FUT2/3, the authors calculated an optimal cut-off of CA19-9 associated with the risk of 
developing CCA. Overall, the inclusion of the FUT2/3 SNP-adjusted cut-off significantly improved the 
sensitivity of CA19-9 in detecting PSC-CCA cases, and have resulted in a 42.9% reduced risk of false 
positive18.  
 
Genomic aberrations and patient classification: Impact on clinical management 
To date, genomic characteristics19,20 and stratification21,22 of CCA patients have been analysed in 
several studies based on high-throughput genomics. For example, Jiao et al. performed WES of 
patients with intrahepatic CCA (iCCA, n=32) and detected inactivating mutations in chromatin 
remodelling genes (for example ARID1A, PBRM1 and BAP1)23. In turn, Nakamura et al.20 reported the 
presence of mutations in the oncogenes KRAS, PIK3CA, NRAS, GNAS, and ERBB2. In the latter study, 
a comprehensive exome and transcriptome analysis was performed on individuals with iCCA 
(n=145), eCCA (perihilar/pCCA and distal (dCCA) cases) (n=86) as well as GBC (n=29). Interestingly, 
around 40% of cases with biliary cancer proved to have alterations in putative driver genes. For 
example, the PKA gene fusions were specifically found in the eCCA, whereas FGFR2 gene fusions 
were detected in the intrahepatic cases. Likewise, ERBB3 and EGFR mutations were detectable only 
in the setting of GBC20. Interestingly, alterations in the TERT promoter was not found in patients with 
eCCA, whereas it was common in patients with GBC as well as detected in one patient with iCCA. 
These results allude to a different genetic composition of the biliary cancers depending on their 
anatomical localization and thus, emphasize the need of including genomic analyses of the tumor 
samples when making clinical decisions.  
Integrative analysis of 149 samples of iCCA22 allowed identification of 2 unique subclasses: the 
`inflammation class´ and the `proliferation class´ with markedly different activation of signaling 
pathways. For example, in the `proliferation class´, the activation of RAS and MET oncogenic 
pathways, mutations in KRAS and BRAF as well as expression of genes that were previously 
associated with worse outcome in patients with HCC22 may render the use of drugs approved for the 
therapy of HCC as possible therapeutic options in patients with iCCA24. Targeted sequencing on 153 
biliary cancers (70 iCCA, 57 eCCAs and 26 GBCs) demonstrated putative driver-gene mutations in 
most cases (118/153), however, the genetic profiles differed significantly based on the localization of 
the tumor type25. Overall, KRAS, TP53, ARID1A, IDH1/2, PBRM1, BAP1, and PIK3CA genes were the 
most frequently altered whereas mutations in TP53 proved to be independent determinants of 
survival25. Based on the tumor localization different genetic profiles were detected with RAS 
mutations being the most common in dCCA. The above-mentioned genomic diversity in CCA might 
be one of the major reasons for the lack of effective therapies. Indeed, based on the localization of 
the tumor, different pathways seem to be involved and clinically they need to be tackled different. 
As such, Nepal et al.26 recently investigated genome-wide data obtained from 496 iCCA patients. 
From these analyses, the team elucidated unique mutational signatures, co-mutational spectra, 
deregulated signaling pathways, structural alterations and DNA methylation aberrations associated 
with each patient subgroup. To test the clinical implications of the different onco-genetic programs, 
they utilized a drug repositioning approach and screened a library of 525 drugs in patient-matched 
cell models. These findings uncovered the potential of individual mutations to induce substantial 
downstream molecular heterogeneity which in turn could facilitate prediction of therapeutic 
sensitivities for CCA patients using standard targeted genotyping. Indeed, the potential involvement 
of inherited CCA predisposition which might be modulated by exogenous risk factors render the 
whole picture even more complex. For these reasons, large and integrated studies will be necessary 
in the future to bring us closer to personalized diagnostics and therapy in patients with different 
subtypes of CCA.  
 
The molecular make up of advanced cholangiocarcinoma: Is it the same as resected tumors?  
Seventy to eighty percent of CCA patients present at an advanced stage and are not amenable to 
surgical intervention27,28. A great effort is directed toward the development of novel therapeutics for 
these patients. The hope of a personalized approach lies in the ability to use therapeutics specifically 
designed to act against a molecular target that drives tumor growth. However, the main challenge in 
advanced CCA personalized treatment is developing a targeted therapy against the molecular drivers 
of the disease, whilst the knowledge of CCA molecular landscape is limited to small resected tumors. 
Would the molecular targets identified in the early stage be expressed in the advanced disease and, 
above all, would they still represent the main lethal drivers of tumor progression? The lack of 
systemic large genomic studies performed in advanced CCA limits the knowledge to provide 
appropriate answers to these questions. Recent findings suggest that there may be minimal driver 
gene mutations heterogeneity in untreated advanced cancer29. However, it is recognized and 
experimentally verified that tumors evolve under the pressure of systemic therapy30,31, thus making 
the knowledge of the molecular landscape in advanced CCA even more compelling with the 
introduction of adjuvant chemotherapies32. 
The shortage of molecular data on advanced CCA is caused by the paucity of tissue available. CCA 
are often diagnosed with cytology or small biopsies which do not enable a comprehensive and full 
molecular and genomic characterization. Feasibility studies on targeted captured sequencing in 
gastrointestinal cancers within routine clinical practice have shown that sequencing may be 
successful only in a minority of CCA patients (26% in advanced CCA versus >50% advanced colorectal 
cancers)33. In addition, success has often been limited to iCCA narrowing the appreciation of 
genomic differences between different subtypes in the advanced setting. To date, two reports are 
available on the genetic characterization of advanced CCA by targeted sequencing, while no data are 
available on whole genome analyses as well as on transcriptomic landmarks. Ahn et al. pursued the 
first targeted Next Generation Sequencing (NGS) study in formalin-fixed-paraffin-embedded tissues 
from chemotherapy-naïve advanced biliary cancer patients, including 142 iCCA and 31 eCCA34. GBC 
and ampullary cancers were included but represented less than 5% of the whole series. The study 
covered the entire coding sequence of 236 cancer-related genes with an averaged depth greater 
than 250x. Unfortunately, 25% of cases represented stage I-II disease, as the analysis was performed 
on archival tissue available from resections. The genes most frequently altered were CDKN2A (29%), 
TP53 (28%) and KRAS (22%), followed by ARID1A and IDH1 (13%), FGFR2 (12%), PI3KCA (10%), 
SMAD4 (190%), PBRM1 (10%). The genes involved were the same identified in studies performed in 
resected CCA. However, each tumor had a median of 3 actionable mutations, with a trend toward an 
increased number of mutations in advanced tumors compared to early stages. In the cohort of 86 
patients with advanced disease who underwent palliative first line chemotherapy no individual gene 
mutations were predictive factors of response to chemotherapy. However, loss of function 
mutations in CDKN2A and TP53 were significantly associated to worse overall survival. Whether this 
is related to the prevalence of these mutations in this cohort remains to be addressed. ARID1A 
mutations, in presence of mutations in TP53 or CDKN2A, were associated to a more chemosensitive 
phenotype to platinum regimen likely through its role in DNA damage, but further studies are 
warranted to validate these findings. More recently data on the advanced biliary cancer cohort of 
the MOSCATO 01 trial have been released. MOSCATO 01 was a prospective clinical trial which 
evaluated the benefit of incorporation of genomic analyses in the selection of systemic therapy for 
advanced cancer patients35. Among 1035 patients enrolled in MOSCATO 01, 4% had advanced biliary 
cancers (N=43) with 67% being iCCA. In this case molecular analysis was completed for 79% of 
patients36. The high rate of success is likely to be related to the clinical trial frame with on-purpose 
research biopsies, the collection of fresh frozen tissue and the prevalence of iCCA in the series. If the 
genes mutated in advanced CCA reflected those identified in the early stage disease (TP53 26%; RAS 
24%; IDH 18%; FGFR 1/2 16%; EGFR and ERBB 16%, CDKN2 16%, PTEN 14%, PI3KCA 10%, and MDM2 
10%), it is interesting to note that multiple molecular alterations were detected in 87% of the 
samples with a median of 3 molecular alterations per patients. These data are interesting when they 
are compared to the molecular landscape of resected tumors in which the co-occurrence of two or 
more actionable lesions is present only in 30% of cases37, and probably provide the bases for 
understanding the failure of targeted therapies in advanced CCA. It is noteworthy to observe that 
targeted therapies have given limited benefits also in cases of highly selected sub-populations, as in 
the case of FGFR2 inhibitors in FGFR2-fused iCCA: the response rate of only 18% suggests that 
progression of these advanced CCA is driven by multiple forces most of which are still unknown38. A 
better knowledge of the interplay between multiple pathways in promoting tumor progression and 
drug resistance in the advance setting is essential for the development of ad-hoc treatment 
combinations and adaptive therapies that enable a long-term control of the disease. In line with this 
hypothesis multiregional sequencing studies have recently shown that parallel evolution and 
chromosomal alteration can shape spatial heterogeneity and promote branch diversity in iCCA39.  
The availability of tissue from the primary and the recurred tumor in one case allowed Dong et al to 
assess the temporal evolution of iCCA39. Multiple mutational clusters were present at a sub-clonal 
occurrence in more than one area in the recurrent tissue, indicating a polyclonal metastatic seeding 
pattern in CCA (Figure 1). We can then speculate that two or more primary clones can be 
responsible for metastatic progression, either because a synergistic cooperation between the 
clusters may prove beneficial in the evolutionary dynamics, or because an early colonization may 
remodel the microenvironment to facilitate colonization of further clones. Interestingly the number 
of clonal mutations was the same between the primary and the recurred tumors, but the number of 
sub-clonal mutations was lower in the recurrence suggesting that only the fittest clones can develop 
and give rise to advanced disease making the molecular profile of advanced tumors different from 
their matched primary. In addition, new oncogenic events can occur in the metastatic tumors that 
contribute to a different profile. Interestingly, Dong et al observed new mutations in the recurrence 
which were not present in the primary tumor and were known to be associated to chemo-
resistance39. 
Taken altogether these data underline the importance of understanding the molecular landscape of 
advanced CCA in order to be able to develop novel effective therapeutic strategies. Two different 
strategies could be implemented to overcome the issues related to lack of tissues from advanced 
CCA: 1) establishment of primary cell lines, and 2) liquid biopsies. Generation of primary cell lines 
from advanced biliary cancers was shown to be feasible through generation of 2D cell lines or 3D 
organoid models39-41; they will have the advantage of enabling expansion of tumor cells and 
achievement of cell purity for a comprehensive characterization of the molecular make-up of tumor 
cells, even though their representation of the intra-patient heterogeneity will be limited by sampling 
bias. Liquid biopsy may represent a promising technology to identify the clones that drive the 
progression of the tumor and the process of metastasis; however, given the limited number of 
circulating tumor cells in CCA, the studies are likely to be limited to the analysis of the mutational 
profile through the assessment of circulating free DNA. 
 
Epigenetic deregulation of cholangiocarcinoma. Clinical implications  
In recent years, it has become apparent that genetic alterations may not fully explain the rapid 
progression and high chemoresistance of CCA42,43. Epigenetic perturbations may play an important 
role in these processes and have, therefore, received increasing attention. In addition, epigenetic 
alterations have been proposed to function as oncogenic drivers and constitutional epimutations 
have been proposed to be the missing link of cancer heritability44,45. Supporting this hypothesis, a 
multitude of epigenetic alterations, including DNA methylation, histone post-translational 
modifications, chromatin remodeling and non-coding RNA have been identified in CCA. Interestingly, 
these different epigenetic pathways are interconnected resulting in alterations of multiple 
epigenetic factors during cholangiocarcinogenesis46-49. Here, we give an overview of recent findings 
and assess the potential clinical implications of targeting epigenetic alterations. 
 
Aberrant methylation status in cholangiocarcinoma 
DNA methylation is a major epigenetic mark with important roles in gene regulation during normal 
development and cancer50. Thereby, genomic DNA is mainly methylated at CpG dinucleotides by 
DNA methyltransferases (DNMTs) and de-methylation is carried out by Ten-eleven translocation 
methylcytosine dioxygenases (TETs). Interestingly, frequent genetic alterations of epigenetic key 
players have been observed in CCA implicating specific epigenetic processes in 
cholangiocarcinogenesis51. Deletion of or mutation in genes encoding the chromatin remodeling 
enzymes BAP1, ARID1A (AT-rich interactive domain-containing protein1A) and PBRM1, or IDH 
(isocitrate dehydrogenase) gain-of-function mutations are the most common alterations perturbing 
the epigenetic landscape of iCCA19,52,53. The tumor suppressor BAP1 is a deubiquitinase which 
participates in chromatin remodeling, whereas, PBRM1 and ARID1A are both subunits of the 
chromatin remodeling complexes SWI/SNF19. However, the inactivation of these chromatin 
remodelers by mutation makes it difficult or may make it even impossible to reactivate them. 
Therefore, it will be crucial to better understand the downstream signaling events induced by 
inactivation of BAP1, PBRM1 and ARID1A hopefully leading to specific treatment regimens for CCA 
patients with inactivation of these chromatin remodelers. 
An integrative genomic analysis of CCA identified distinct IDH-mutant molecular profiles which 
define a distinct CCA subtype43. IDH mutations alone have been shown to be sufficient to induce a 
hypermethylator phenotype54 and they tend to appear more frequently in recurrent iCCA with gene 
expression traits of epithelial-mesenchymal transition55. However, an integrative analysis of genetic 
and epigenetic profiles revealed that a subgroup of CCA patients with high rate of IDH or BAP1 
mutation and CpG shore hypermethylation had better prognosis compared to other patient groups 
56,57. Thus, it is still under debate whether epigenetic alterations, caused by specific mutations of 
epigenetic modulators or by other mechanisms, may drive tumor development and progression. 
Gain-of-function mutations of IDH occur in mutational hotspots affecting R132 of IDH1 and R172 of 
its mitochondrial isozyme IDH257. Interestingly, IDH mutations seem to exclusively occur in iCCA but 
not in pCCA and dCCA37. The frequency of IDH mutations has been reported to differ between 
cohorts with 5%, 6.1%, 18.6% and 31% in a Chinese, Japanese, Italian and US American cohort, 
respectively37,58,59. Mechanistically, IDH1 and IDH2 gain-of-function mutations lead to the 
neomorphic production of the oncometabolite 2-hydroxyglutarate (2-HG) which impairs DNA 
demethylation by TET260,61. This leads to hypermethylated CpG sites significantly enriched in CpG 
shores and upstream of transcription start sites predominantly targeting other epigenetic regulators 
57. Thus, the additional repression of epigenetic regulators by IDH mutation potentiates and 
potentially synergizes to induce tumorigenic effects. However, IDH-mutant CCA did not exhibit the 
largest average DNA methylation and share hypermethylation targets with glioblastomas, suggesting 
the contribution of additional specific factors outside the DNA methylation pathways51,57. 
Based on histology iCCAs can be subdivided into two groups: the bile duct-type which resembles 
eCCA with columnar cells with mucin production and the cholangiolar-type which recapitulates a 
small-duct iCCA morphological pattern with cell-rich tubuli formed by cuboidal cells without 
extracellular mucin62. It is likely that these two histological subtypes of iCCA have distinct cells-of-
origin62. Consistent with the almost exclusive detection of IDH mutations in iCCA, cholangiolar-type 
iCCA show a higher frequency of IDH mutations compared to bile duct-type iCCA37,62. The distinct 
profiles of IDH-mutant iCCA suggest that this subgroup of iCCA patients may be ideal candidates for 
targeted therapies. In addition, the circulating oncometabolite 2-HG, resulting from IDH gain-of-
function mutation, may be used as a surrogate biomarker for patients with IDH mutation59. In 
glioblastoma, IDH mutation decreased the levels of STAT1 and the accumulation of T cells in tumor 
sites suggesting a mechanism of immune evasion63. Targeted therapies for IDH mutant tumors are 
already in clinical trials and may alone or in combination with immunotherapies improve patient 
outcome64,65. 
However, besides cases with IDH-mutation additional CCA cases exhibit distinct DNA methylation 
profiles some of which have a larger average of altered DNA methylation compared to IDH-mutant 
CCA. Thus, multiple mechanisms may lead to distinct DNA methylation profiles. Recent studies in 
CCA suggest that promoter hypermethylation of tumor suppressor genes may be a key event of CCA 
progression and the non-random binomial distribution of hypermethylation patterns suggests 
specific mechanism inducing these DNA methylation alterations56,66,67. The inactivation of tumor 
suppressive genes by hypermethylation was successfully reversed using DNMT inhibiting cytidine 
analogues, such as 5‐aza‐2′‐deoxycytidine (decitabine), in vitro66-68. The cytidine analogues 5‐aza‐2′‐
deoxycytidine and 5-azacytidine received approval for the treatment of hematologic malignancies 
and have gained interest as priming agents in the treatment of solid tumors69. But 5-aza-2′-
deoxycytidine has been reported to be mutagenic70 and cytidine analogue chemotherapeutics are 
rapidly metabolized into inactive uridine counterparts by the enzyme cytidine deaminase (CDA) 
which is highly expressed in the liver71,72. Therefore, it may be difficult to reach adequate levels of 
cytidine analogue within the liver. Zebularine is a second-generation nucleoside analog with 
increased stability compared to 5‐aza‐2′‐deoxycytidine and 5-azacytidine. The identification of CCA 
patients with a responder gene signature may aid in the identification of patients who may benefit 
from Zebularine treatment73,74. Thus, it will be important to identify potent DNMT inhibitors and a 
subgroup of CCA patient who will most like respond to DNMT inhibition. 
 
Post-transcriptional modifications and non-coding RNA landscape 
Non-coding RNAs (ncRNAs) are single stranded RNA molecules which are not translated into protein. 
NcRNAs can regulate multiple cellular pathways and they are divided into two subclasses based on 
their length: long ncRNA (lncRNA; >200nt) and small ncRNA (<200nt). Small ncRNAs are less than 
200nt long and include microRNA (miRNA; 19-25nt), small interfering RNA (siRNA; 19-25nt), piwi-
RNA (piRNA; 26-32nt) and small nucleolar RNA (snoRNA; >60nt). Of these ncRNAs, miRNAs have 
been studied most in cancer. The mainly function of miRNAs is the inhibition of protein translation, 
whereas, lncRNAs appear to exhibit diverse functions through forming secondary and tertiary 
structures regulating multiple cellular processes. 
Depending on their target genes, miRNAs may function as oncogenes or tumor suppressors and 
miRNA profiling may be useful for patient stratification or to classify poorly differentiated 
tumors47,75,76. The first miRNAs and anti-miRs are now in clinical trials demonstrating that both, 
oncogenic and tumor suppressive miRNAs, may be successfully targeted. In CCA, most studies used a 
candidate approach focusing on a single miRNA. MiR-21 has been suggested to function as an 
oncogene and consistently miR-21 is upregulated in CCA77, increases cell invasion52 and decreased 
sensitivity to gemcitabine78. In addition, circulation miR-21 has been found to be increased in plasma 
of iCCA patients and together with miR-221 it has been proposed to be a non-invasive diagnostic 
marker for iCCA79. In contrast, a dual role of the miR-200 family (miR-200a, miR-200b, miR-429 in 
one cluster, and miR-200c and miR-141 in a second cluster) may exist. On one hand, miR-200c and 
miR-141 are downregulated in CCA and induces epithelial-to-mesenchymal transition (EMT) and cell 
invasion80. On the other hand, miR-200a, miR-200b and miR-429 are hypomethylated and may target 
the tumor suppressor genes DLC1, FBXW7 and CDH649. Thus, miR-200 family members may exhibit 
different functions depending on the cellular context or CCA subtype. The let-7 family members, let-
7a81-83, let-7b81, let-7c84, let-7d83, let-7e83 and let-7f83, are downregulated in iCCA and have been 
shown to inhibit self-renewal capacity and subcutaneous cancer cell growth in vivo84,85. In 
concordance, inhibition of let-7a in bile duct-ligated mice increased intrahepatic bile duct mass and 
expression of nerve growth factor86. Deregulated expression of miRNAs may also lead to alteration in 
DNA methylation. MiR-191 expression is increased in iCCA promoting proliferation, invasion, and 
migration87. The DNA demethylase TET1 is a direct target of miR-191 and reduced TET1 expression in 
CCA increased DNA methylation at the TP53 gene transcription start site resulting in reduced p53 
expression87. Although, these studies show that miRNAs may play key roles in 
cholangiocarcinogenesis, it is still unclear how these miRNAs may be exploited as therapeutic 
targets. Only few miRNAs have been confirmed to be deregulated in CCA by independent studies. 
This might be caused by the use of relatively small cohorts which differed greatly in etiology, CCA 
subtypes and ethnicity. Thus, larger cohorts are needed to identify relevant patient subgroups which 
may benefit from miRNA-based targeted therapies. 
Interestingly, miRNAs may themselves be targeted by lncRNA, thereby, inhibiting the miRNA’s 
function. LncRNAs may act as regulatory factors by presenting `decoy´ binding sites which bind 
miRNAs leading in turn to reduced inhibition of the miRNA’s targets and thus, functioning like a 
miRNA `sponge´88. The lncRNA H19 may bind let-7a which can no longer inhibit IL6 a potent 
antiapoptotic signaling mechanism in CCA89-91. Another example, of sponging is the lncRNA HULC 
which may bind miR-372 and miR-373 leading to increased expression of their target CXCR4 91. The 
lncRNA NEAT1 is a functional downstream target of BAP1 and negatively regulated by BAP192. BAP1 
expression is reduced in CCA inducing NEAT-1 expression and decreasing cytotoxicity to 
gemcitabine92. Although, the role of lncRNAs has received increasing attention during the last years 
and large numbers of lncRNAs have bene shown to be differentially expressed, only little is known 
about the function of lncRNAs. It is also crucial to analyze larger cohorts to better understand their 
function in CCA. A recent large-scale CRISPR-based screen assessing the function of ∼17,000 lncRNAs 
in seven human cell lines found that the function of lncRNAs was highly cell type-specific, often 
limited to just one cell type93. Given the large heterogeneity of CCA between anatomical subtypes 
and different etiologies, it is highly likely that most lncRNAs are functional in a subset of CCA only. 
Thus, additional research is needed to understand the concrete function of lncRNAs in CCA patient 
subgroups and to potentially utilize or target lncRNAs in the clinic. 
 CONCLUDING REMARKS 
Aside from being categorized by heterogeneous anatomic location, CCA is categorized based on 
histopathological analysis and by growth-type patterns as well. A prominent histological feature of 
CCA is the abundant desmoplasia (tumor stroma), which is a fibrogenic tissue completely 
surrounding and tangled into the tumor epithelia and constitutes myofibroblasts, immune cells and 
vessels. This is a milieu that supports active cross-talk between the stromal and epithelial tumor cells 
and plays a causal role in tumor onset, metastasis and the pronounced drug resistance. CCA is highly 
heterogeneous not only in initiation and location but in progression as well, making it difficult to 
categorize CCA into distinct molecular subtypes. It is apparent that our current approaches to CCA 
are lacking as evidenced by the continued poor survival rates and limited treatment options. For 
these reasons, it is critical that new and effective therapies be developed. Indeed, most patients are 
diagnosed at a stage with locally advanced disease or distal metastasis when 705 to 90% of the 
patients are ineligible for surgery. Even amongst patients, who undergo surgery, more than 50% of 
cases are at risk of developing recurrence within 12 months due to inadequate adjuvant 
therapy94. Therefore, understanding the causal biology of CCA metastasis is urgently needed.  
A comprehensive and multi-layered understanding of the disease pathogenesis is fundamental in the 
development of novel therapeutic strategies. For example, the inception of epigenomic profiling 
technologies rapidly confirmed such modes of genetic regulation to be far more complex than 
traditional genomics, invoking new challenges in experimental design and interpretation. CCA lags 
behind the majority of cancers in epigenomics, though this may afford opportunity to prospectively 
in the future design robust molecular studies. We need to focus on genome-wide integromics for 
patient characterization, stratification and discovery of biomarkers to advance early diagnosis and 
precision therapy. Thus, to get to this stage in the clinical management of cholangiocarcinoma, it will 
be essential to further 1) elucidated the genome perturbations that dictate unique regulatory 
networks in primary and metastatic sites, 2) delineated synergistic drug repositioning and 
chemosensitization in CCA, 3) investigate the role of desmoplastic stromal cells in CCA tumor growth 
and resistance to treatment (for example the potential for immunotherapy targeting this niche), 4) 
comprehensively define the involvement of DNA methylation regions in transcriptional regulation 
and as driving factors in CCA, and capitalize on the potential of epigenome-based targeted therapy. 
Finally, we currently know surprisingly little about 5) the role of non-coding RNAs both as markers in 
CCA diagnosis and prognosis, and importantly also as regulators in drug responses.  
 
FIGURE LEGEND 
Figure 1. Schematic representation of the changes occurring in the molecular make-up of 
advanced CCA. (A) Little information is available on the molecular landscape of advanced CCA and 
on the evolutionary dynamics of these tumors. Based on evidence available so far, we can speculate 
that CCAs have polyclonal seeding potential where only the fittest clones survive. In addition, 
emergence of new clones induced by anti-cancer treatment has been detected in isolated cases of 
relapsed CCA which were not present in the primary tumor. (B) The differences in the molecular 
profile of primary and advanced cancers can be explained according two different hypotheses. There 
is evidence that isolated cancer cells with a specific phenotype can initially form a pre-metastatic 
niche, causing changes in the stroma that in turns induces molecular and phenotypic changes of the 
cancer cells that will populate the metastatic deposit. The poly-clonality of the metastatic deposit 
may alternatively be justified by a potential synergism of cancer clones that can give rise to a 
metastatic growth only when their oncogenic properties are combined. 
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